Literature DB >> 25102947

Lymphodepletion followed by infusion of suicide gene-transduced donor lymphocytes to safely enhance their antitumor effect: a phase I/II study.

S Maury1, M Rosenzwajg2, R Redjoul3, A Marcais4, A Xhaard5, M Cherai6, L Cabanne3, G Churlaud7, F Suarez4, G Socié5, L Gregoire8, K Debbache3, C Bernard9, J-L Beaumont10, N Azar7, O Boyer11, F Roudot-Thoraval12, J L Cohen13, C Cordonnier14, F M Lemoine15, D Klatzmann2.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25102947     DOI： 10.1038/leu.2014.237

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Genetically modified donor leukocyte transfusion and graft-versus-leukemia effect after allogeneic stem cell transplantation.

Authors:  Sylvia Borchers; Elena Provasi; Anna Silvani; Marina Radrizzani; Claudia Benati; Elke Dammann; Annika Krons; Julia Kontsendorn; Joerg Schmidtke; Wolfgang Kuehnau; Nils von Neuhoff; Michael Stadler; Fabio Ciceri; Chiara Bonini; Arnold Ganser; Bernd Hertenstein; Eva M Weissinger
Journal:  Hum Gene Ther       Date:  2011-03-30       Impact factor: 5.695

2.  Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft.

Authors:  P Tiberghien; C Ferrand; B Lioure; N Milpied; R Angonin; E Deconinck; J M Certoux; E Robinet; P Saas; B Petracca; C Juttner; C W Reynolds; D L Longo; P Hervé; J Y Cahn
Journal:  Blood       Date:  2001-01-01       Impact factor: 22.113

3.  NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  David L Porter; Edwin P Alyea; Joseph H Antin; Marcos DeLima; Eli Estey; J H Frederik Falkenburg; Nancy Hardy; Nicolaus Kroeger; Jose Leis; John Levine; David G Maloney; Karl Peggs; Jacob M Rowe; Alan S Wayne; Sergio Giralt; Michael R Bishop; Koen van Besien
Journal:  Biol Blood Marrow Transplant       Date:  2010-08-10       Impact factor: 5.742

Review 4.  Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation.

Authors:  Nicoletta Cieri; Sara Mastaglio; Giacomo Oliveira; Monica Casucci; Attilio Bondanza; Chiara Bonini
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

5.  Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone.

Authors:  Jeffrey S Miller; Daniel J Weisdorf; Linda J Burns; Arne Slungaard; John E Wagner; Michael R Verneris; Sarah Cooley; Rosanna Wangen; Susan K Fautsch; Roby Nicklow; Todd Defor; Bruce R Blazar
Journal:  Blood       Date:  2007-06-19       Impact factor: 22.113

6.  Herpes simplex thymidine kinase gene-transduced donor lymphocyte infusions.

Authors:  Richard K Burt; William R Drobyski; Tatiana Seregina; Ann Traynor; Yu Oyama; Carolyn Keever-Taylor; Jacob Stefka; Timothy M Kuzel; Mary Brush; Julianne Rodriquez; Willam Burns; Lucinda Tennant; Charles Link
Journal:  Exp Hematol       Date:  2003-10       Impact factor: 3.084

7.  Efficient transduction and selection of human T-lymphocytes with bicistronic Thy1/HSV1-TK retroviral vector produced by a human packaging cell line.

Authors:  François M Lemoine; Mariana Mesel-Lemoine; Mustapha Cherai; Géraldine Gallot; Henri Vié; Virginie Leclercq; Hélène Trébèden-Negre; Olivier Mammès; Olivier Boyer; Patricia Noguiez-Hellin; David Klatzmann
Journal:  J Gene Med       Date:  2004-04       Impact factor: 4.565

8.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

Authors:  Stephan A Grupp; Michael Kalos; David Barrett; Richard Aplenc; David L Porter; Susan R Rheingold; David T Teachey; Anne Chew; Bernd Hauck; J Fraser Wright; Michael C Milone; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2013-03-25       Impact factor: 91.245

9.  Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety.

Authors:  V Hoyos; B Savoldo; C Quintarelli; A Mahendravada; M Zhang; J Vera; H E Heslop; C M Rooney; M K Brenner; G Dotti
Journal:  Leukemia       Date:  2010-04-29       Impact factor: 11.528

10.  Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study.

Authors:  Fabio Ciceri; Chiara Bonini; Maria Teresa Lupo Stanghellini; Attilio Bondanza; Catia Traversari; Monica Salomoni; Lucia Turchetto; Scialini Colombi; Massimo Bernardi; Jacopo Peccatori; Alessandra Pescarollo; Paolo Servida; Zulma Magnani; Serena K Perna; Veronica Valtolina; Fulvio Crippa; Luciano Callegaro; Elena Spoldi; Roberto Crocchiolo; Katharina Fleischhauer; Maurilio Ponzoni; Luca Vago; Silvano Rossini; Armando Santoro; Elisabetta Todisco; Jane Apperley; Eduardo Olavarria; Shimon Slavin; Eva M Weissinger; Arnold Ganser; Michael Stadler; Evangelia Yannaki; Athanasios Fassas; Achilles Anagnostopoulos; Marco Bregni; Corrado Gallo Stampino; Paolo Bruzzi; Claudio Bordignon
Journal:  Lancet Oncol       Date:  2009-04-01       Impact factor: 41.316
View more
  8 in total

Review 1.  Regulatory T cells in the treatment of disease.

Authors:  Amir Sharabi; Maria G Tsokos; Ying Ding; Thomas R Malek; David Klatzmann; George C Tsokos
Journal:  Nat Rev Drug Discov       Date:  2018-10-12       Impact factor: 84.694

Review 2.  Improving the safety of cell therapy with the TK-suicide gene.

Authors:  Raffaella Greco; Giacomo Oliveira; Maria Teresa Lupo Stanghellini; Luca Vago; Attilio Bondanza; Jacopo Peccatori; Nicoletta Cieri; Sarah Marktel; Sara Mastaglio; Claudio Bordignon; Chiara Bonini; Fabio Ciceri
Journal:  Front Pharmacol       Date:  2015-05-05       Impact factor: 5.810

3.  Molecular Approaches to Safe and Controlled Engineered T-cell Therapy.

Authors:  R S Kalinin; A V Petukhov; V D Knorre; M A Maschan; A V Stepanov; A G Gabibov
Journal:  Acta Naturae       Date:  2018 Apr-Jun       Impact factor: 1.845

Review 4.  Current Preventions and Treatments of aGVHD: From Pharmacological Prophylaxis to Innovative Therapies.

Authors:  Sina Naserian; Mathieu Leclerc; Sara Shamdani; Georges Uzan
Journal:  Front Immunol       Date:  2020-12-17       Impact factor: 7.561

Review 5.  Noninvasive Imaging of Cancer Immunotherapy.

Authors:  Omar Abousaway; Taha Rakhshandehroo; Annick D Van den Abbeele; Moritz F Kircher; Mohammad Rashidian
Journal:  Nanotheranostics       Date:  2021-01-01

6.  TNFR2 blockade of regulatory T cells unleashes an antitumor immune response after hematopoietic stem-cell transplantation.

Authors:  Anais Debesset; Caroline Pilon; Audrey Moatti; Asma Beldi-Ferchiou; Mathieu Leclerc; Rabah Redjoul; Frederic Charlotte; Nhu Hanh To; Adeline Bak; Yazid Belkacemi; Benoît Laurent Salomon; Fadi Issa; David Michonneau; Sebastien Maury; José Laurent Cohen; Allan Thiolat
Journal:  J Immunother Cancer       Date:  2022-04       Impact factor: 12.469

7.  Neomorphic DNA-binding enables tumor-specific therapeutic gene expression in fusion-addicted childhood sarcoma.

Authors:  Thomas G P Grünewald; Maximilian M L Knott; Tilman L B Hölting; Florencia Cidre-Aranaz; Dana Matzek; Bastian Popper; Severin J Jacobi; Cornelius M Funk; Florian H Geyer; Jing Li; Ignazio Piseddu; Bruno L Cadilha; Stephan Ledderose; Jennifer Zwilling; Shunya Ohmura; David Anz; Annette Künkele; Frederick Klauschen
Journal:  Mol Cancer       Date:  2022-10-13       Impact factor: 41.444

8.  Inflammation and tumor progression: signaling pathways and targeted intervention.

Authors:  Huakan Zhao; Lei Wu; Guifang Yan; Yu Chen; Mingyue Zhou; Yongzhong Wu; Yongsheng Li
Journal:  Signal Transduct Target Ther       Date:  2021-07-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.